EGFR-mutant non-small cell lung cancer
Conditions
Interventions
Control group:none
Experimental group:none
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years old. 2.Pathologically confirmed stage IIIB or IV non-small cell lung cancer, with a clear pathological classification. 3.Genetic testing of the pathological tissue confirmed EGFR sensitive mutations (including Exon19del or L858R). 4.After first-, second-, or third-line EGFR-TKI targeted therapy, disease progression was confirmed by imaging (according to RECIST 1.1 criteria). 5.After developing resistance to EGFR-TKI, the patient received systemic antitumor treatment other than targeted therapy. 6.Complete baseline clinical, pathological, and imaging follow-up data available.
Exclusion criteria
Exclusion criteria: 1.Diagnosed with mixed small cell lung cancer. 2.With a previous history of other malignant tumors. 3.Repeat pathological tissue genetic testing confirmed the presence of other concomitant positive driver genes, such as MET amplification, HER2 amplification, BRAF V600E, etc. 4.Previously received systemic anti-tumor therapy (including cytotoxic chemotherapy, immunotherapy) other than EGFR-TKIs. 5.The medical records are severely incomplete, making it impossible to evaluate the efficacy or safety.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Progression Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR);Treatment-related adverse events; | — |
Countries
China
Contacts
Public ContactFen Wang
Peking University Shenzhen Hospital
Outcome results
None listed